Metrics to compare | 4147 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4147PeersSector | |
|---|---|---|---|---|
P/E Ratio | −122.1x | −11.5x | −0.4x | |
PEG Ratio | −2.86 | −0.15 | 0.00 | |
Price/Book | 4.6x | 3.0x | 2.6x | |
Price / LTM Sales | 27.4x | 75.9x | 3.0x | |
Upside (Analyst Target) | 189.9% | 0.0% | 57.5% | |
Fair Value Upside | Unlock | −28.3% | 7.8% | Unlock |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.